- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Import alert on Himalaya products at ports by USFDA
The alert termed "Detention Without Physical Examination of Unapproved New Drugs Promoted in the US" by the US government officials
Personal care products manufactured by Himalaya Drug Company at its facilities in Hyderabad, Bengaluru and Himachal Pradesh, has been detained by the US Food and Drug Administration at the ports. The alert has been termed as the "Detention Without Physical Examination of Unapproved New Drugs Promoted in the US" by the US government officials.
As reported by PTI
The alert was imposed on Himalaya's personal cleanliness products (not anti-perspirant) that include popular neem face wash manufactured at Nalagarh, Himachal Pradesh, and anti wrinkle cream manufactured at Peenya Industrial Area, Bengaluru, among others.
When contacted, a company spokesperson said the alert was in respect of colour additives used in the cosmetics and claimed that the products examined by the FDA authorities could have been meant for the Indian market sold in the US illegally.
"All Himalaya cosmetic products sold in the US market adhere to the USFDA guidelines. The import alert is a clarification on the colour additives and we will provide evidence to substantiate the fact that our products developed for the US market conform to the required guidelines.
There could be a possibility that our Indian products, which comply with the domestic regulatory requirements, might have been sold by someone in the US market without our notice and thus, USFDA is seeking a clarification through an import alert," the company said in an emailed reply to PTI.
A senior company official said Himalaya exports its products to more than 90 countries. It has 40-plus manufacturing facilities under loan licensing agreement while two state-of-the-art facilities are owned by the company.
Personal care products manufactured by Himalaya Drug Company at its facilities in Hyderabad, Bengaluru and Himachal Pradesh, has been detained by the US Food and Drug Administration at the ports. The alert has been termed as the "Detention Without Physical Examination of Unapproved New Drugs Promoted in the US" by the US government officials.
As reported by PTI
The alert was imposed on Himalaya's personal cleanliness products (not anti-perspirant) that include popular neem face wash manufactured at Nalagarh, Himachal Pradesh, and anti wrinkle cream manufactured at Peenya Industrial Area, Bengaluru, among others.
When contacted, a company spokesperson said the alert was in respect of colour additives used in the cosmetics and claimed that the products examined by the FDA authorities could have been meant for the Indian market sold in the US illegally.
"All Himalaya cosmetic products sold in the US market adhere to the USFDA guidelines. The import alert is a clarification on the colour additives and we will provide evidence to substantiate the fact that our products developed for the US market conform to the required guidelines.
There could be a possibility that our Indian products, which comply with the domestic regulatory requirements, might have been sold by someone in the US market without our notice and thus, USFDA is seeking a clarification through an import alert," the company said in an emailed reply to PTI.
A senior company official said Himalaya exports its products to more than 90 countries. It has 40-plus manufacturing facilities under loan licensing agreement while two state-of-the-art facilities are owned by the company.
Next Story